We have conducted a genotyping study using a custom Illumina Infinium HD genotyping array, the ImmunoChip, in a new UK sample of 1218 bipolar disorder (BD) cases and 2913 controls that have not been used in any studies previously reported independently or in meta-analyses. The ImmunoChip was designed before the publication of the Psychiatric Genome-Wide Association Study Consortium Bipolar Disorder Working Group (PGC-BD) meta-analysis data. As such 3106 single-nucleotide polymorphisms (SNPs) with a P-value o1 Â 10 À 3 from the BD meta-analysis by Ferreira et al. were genotyped. We report support for two of the three most strongly associated chromosomal regions in the Ferreira study, CACNA1C (rs1006737, P ¼ 4.09 Â 10 À 4 ) and 15q14 (rs2172835, P ¼ 0.043) but not ANK3 (rs10994336, P ¼ 0.912). We have combined our ImmunoChip data (569 quasi-independent SNPs from the 3016 SNPs genotyped) with the recently published PGC-BD meta-analysis data, using either the PGC-BD combined discovery and replication data where available or just the discovery data where the SNP was not typed in a replication sample in PGC-BD. Our data provide support for two regions, at ODZ4 and CACNA1C, with prior evidence for genome-wide significant (GWS) association in PGC-BD meta-analysis. In addition, the combined analysis shows two novel GWS associations. First, rs7296288 (P ¼ 8.97 Â 10 À 9
INTRODUCTION
There is robust evidence that genes influence susceptibility to bipolar disorder (BD). 1, 2 Genome-wide association studies (GWAS) have identified a number of loci, which show strong support for their association with BD including common polymorphisms within CACNA1C, ANK3 and NCAN. 3, 4 Recently, the Psychiatric GWAS Consortium Bipolar Disorder (PGC-BD) group performed a combined analysis of GWAS data from 7481 BD individuals and 9250 controls. A replication study tested 34 single-nucleotide polymorphisms (SNPs) that were associated at P-value o5 Â 10 À 5 in the discovery sample in 4496 independent cases with BD and 42 422 independent controls. The combined analysis of the discovery and replication sample confirmed genome-wide significant (GWS) evidence of association for CACNA1C and identified a new GWS intronic variant in ODZ4. 5 In this study, we have examined previously reported susceptibility loci by genotyping BD cases and controls on the custom content Illumina array, the ImmunoChip. The genotyping was undertaken through our participation in the Wellcome Trust Case Control Consortium Extension study (WTCCC) and included some samples from our earlier GWAS 6 and a new set of cases and controls that have not been reported previously, the latter being the focus of this report. The ImmunoChip was designed to study SNPs and genes covering autoimmune disorders, for example, Coeliac disease, 7 extensive SNP data from the major histocompatibility complex region and regions of interest for followup and fine mapping arising from previous GWAS studies of a number of clinical phenotypes studied in the WTCCC studies, including BD. The SNP content relevant to BD was chosen from the BD meta-analysis by Ferreira et al., 3 taking SNPs with a P-value o10 À 3 . As the ImmunoChip was designed before the publication of the large PGC-BD meta-analysis 5 the most significantly associated SNPs from this meta-analysis were not specifically included, although some were on the chip because they were also strongly associated within the meta-analysis for Ferreira et al. 3 (which included samples that were part of the PGC-BD analysis).
In this study, we report the results from SNPs both chosen from the BD meta-analysis 3 and 21 (directly genotyped or proxies) of the 34 most significantly associated SNPs from the PGC-BD study. 5 We also describe fine mapping data for CACNA1C and ANK3.
1

MATERIALS AND METHODS Samples
All the participants in these studies were unrelated, white, living in the British Isles and were of European descent. The protocols and procedures were approved by the relevant ethics review panels where patients were recruited.
BD cases
The individuals were recruited if they suffered with a major mood disorder in which clinically significant episodes of elevated mood had occurred. Bipolar cases were excluded if they: (i) had experienced mood or psychotic illness only as a result of alcohol or substance dependence; (ii) had experienced mood or psychotic illness only secondary to medical illness or medication; or (iii) were biologically related to another study participant. The following methodology was used for assessment of bipolar cases: a semi-structured lifetime ever psychiatric interview (Schedules for Clinical Assessment in Neuropsychiatry), 8 a review of the available case notes and completion of the Operational Criteria (OPCRIT) checklist of items of psychopathology, 9 which has been shown to be valid in studies of mood disorders, 10 followed by clinical ratings and a best-estimate lifetime diagnosis according Research Diagnostic criteria. 11 In cases where there was doubt as to the best-estimate lifetime diagnosis, diagnostic and clinical ratings were made by at least two members of the research team blind to each other's ratings.
Independent new BD cases
The independent cases consisted of 1218 individuals of which 29% were male. The mean age of recruitment was 46 (s.d. 12) years, with a mean age at first impairment because of BD of 22 (s.d. 9) years. A lifetime diagnosis was made according to Research Diagnostic Criteria 11 and the 1218 individuals were categorized as follows: bipolar I disorder/mania: 63% cases, bipolar II disorder/hypomania: 29% cases, schizoaffective disorder, bipolar type: 8% cases. Of those individuals for whom we were able to make a definite rating, 65% of the cases had a lifetime experience of psychotic symptoms (defined as a score over 9 on the Bipolar Affective Disorder Dimension Scale (BADDS)) 12 and 25% had a lifetime experience of predominantly mood-incongruent psychotic symptoms (defined as a score over 29 on the BADDS 12 mood incongruence scale).
Additional BD cases
The 1368 additional BD cases had been previously genotyped as part of the BD sample for the WTCCC GWAS. 6 In combination with the independent BD cases described above, these additional cases were used for the fine mapping analyses in this report.
Of these 1368 cases, 37% were male, with a mean age at recruitment of 48 (s.d. 13) years and a mean age at first impairment because of BD of 25 (s.d. 10) years. A lifetime diagnosis according to RDC 11 was made as follows: bipolar I disorder/mania: 78% cases, bipolar II disorder/hypomania: 6% cases, schizoaffective disorder, bipolar type: 16% cases. Of those individuals for whom we were able to make a definite rating, 70% of the cases had a lifetime experience of psychotic symptoms (defined as a score over 9 on the BADDS 12 and 30% had a lifetime experience of predominantly moodincongruent psychotic symptoms (defined as a score over 29 on the BADDS 12 psychosis and mood incongruence scale).
Controls
The controls, which were not screened to exclude presence of psychiatric illness, came from two sources: the 1958 Birth Cohort (58C) Controls and the UK blood service (UKBS) controls. The characteristics and recruitment of both are described in WTCCC. 6 
Independent new controls
There were 2913 controls in the independent sample, of which 47% were male.
Additional controls
The additional controls consisted of 1409 samples of which 48% were males. A total of 5 of these samples were part of the 58C and 1404 from UKBS control samples, which had been genotyped in the earlier GWAS. 6 
Genotyping
ImmunoChip design was undertaken centrally at the Sanger Institute and the genotyping of the BD samples using this chip was performed at the Wellcome Trust Sanger Institute within the context of our participation in WTCCC. The ImmunoChip is a consortium based, custom Illumina Infinium HD genotyping array. The array was designed to study SNPs and genes covering 12 autoimmune disorders, extensive SNP data from the major histocompatibility complex region and regions of interest for follow-up arising from previous GWAS studies of a number of clinical phenotypes studied in the WTCCC, including BD. To supplement the fine mapping SNPs, 1000 Genomes Project pilot CEU population variants (September 2009 release) were included. Finally, investigator-specific 'wildcard' SNPs were also submitted and it is this content (see section below) that forms the basis for this report BD (investigator-specific) SNPs selection for replication
We selected SNPs for replication from the Ferreira et al.
3 meta-analysis of the STEP-UCL, WTCCC and ED-DUB-STEP2 studies, which included a total of 4387 cases and 6209 controls. All SNPs from this study with a P-value r1 Â 10 À 3 were submitted to be included on the ImmunoChip.
SNPs selection for fine mapping of the genes: CACNA1C and ANK3 SNAP (SNP Annotation and Proxy Search) (http://www.broadinstitute.org/ mpg/snap/) was used to define recombination points around the SNPs of interest using the genotype data from the original BD meta-analysis. 
Statistical analysis
Central analysis group (Sanger) quality control of the data. Unless stated otherwise, all data management and quality control assessment were performed with PLINK (v1.07) 13 and a series of shell scripts. All genotypes were called with the GenoSNP software 14 and any genotypes with a call probability o85% were scored as missing data. Following preliminary quality control assessment by the Sanger central data pipeline, data on 2893 BD and 4539 control individuals were made available to us, genotyped for 192 402 autosomal SNPs.
Association analyses of the independent sample
The genomic inflation factor (l), calculated as the ratio between the observed and expected median w 2 statistic using the 43K SNPs in relative linkage equilibrium was 1.017 (l 1000 ¼ 1.01) and was used to correct for the degree of inflation. To explore potential effects of population stratification within the sample, combinations of the first 10 principal components from Eigenstrat were included as covariates in a logistic regression analysis (additive model). The first principal component had a noticeable effect on the genomic control l statistics. Logistic regression of disease state was preformed with one covariate (the first principal component from Eigenstrat analysis) using PLINK. 13 Post QC quantile-quantile (Q-Q) plots are shown in Supplementary Figure 1 .
Meta-analyses
Results from the current analysis were combined with data from published analyses by fixed-effects meta-analysis using PLINK 1.07 13 to estimate a common odds ratio (OR) weighted by individual study's s.e. The sample sets used were; our independent ImmunoChip data; the PGC-BD discovery data GC adjusted based on a l of 1.148 (that is, the l calculated for the PGC-BD data set), or the PGC combined GWAS and replication data, which had been previously adjusted by a l of 1.176 5 (if the SNP or a proxy of the SNP was one of the 34 SNPs in the PGC-BD replication study). If a SNP was not present in our ImmunoChip data, a proxy SNP in strong linkage disequilibrium (LD) (D 0 ¼ 1, r 2 Z0.8) was substituted and the s.e. weighted (s.e.w.) to account for the lack of information: s.e.w. ¼ s.e./sqrt(r 2 ).
Fine mapping using independent and additional sample
For the fine mapping analyses, logistic regression was used to investigate the possibility of more than one independent signal in CACNA1C after accounting for the effects of the most strongly associated SNP.
RESULTS
We genotyped in an independent sample (1218 BD individuals and 2913 controls) the most significant SNPs in a BD metaanalysis 3 including those that had surpassed a P-value of o1 Â 10 À 3 (n ¼ 3016, list in Supplementary Table S4; see  Supplementary Table 2 for the association results for all SNPs with a P-value o10 À 2 ). The 3016 SNPs were reduced to a subset of 569 quasi-independent SNPs by removing one SNP from each pair of SNPs with r 2 40.5. The SNP that was removed in each case was the one with the least significant P-value in the Ferreira et al. study. A sign test for consistency of direction of effect between the meta-analysis study and our independent ImmunoChip study for the 569 SNPs was highly significant (sign test P-value, 5.32
). The same direction of effect was observed in 343 of the 569 (60%) SNPs. By reducing the level of dependence between the SNPs and applying a r 2 value of 40.2 and performing the same analysis we also noted a highly significant sign test (P ¼ 3.36 Â 10 À 6 ) for the consistency of direction of effect, 288 of the 477 (60%) SNPs had the same direction of effect.
For these 569 independent SNPs, we combined the PGC-BD primary data set (7481 BD cases and 9250 controls) with our independent ImmunoChip data set. In Table 1 , we report 6 SNPs that do not overlap with the 34 SNPs genotyped in the PGC-BD 5 replication sample, and that reached significance levels of P-value o10 À 5 . One SNP, rs3818253, on chromosome 20q11 met GWS (P ¼ 3.88 Â 10 À 8 , OR ¼ 1.164). Within this new GWS LD region are the genes GSS, MYH7B and TRPC4AP.
Within the independent ImmunoChip sample, data were available for 21 of the 34 top SNPs in the PGC-BD replication study. In all, 13 SNPs had been directly genotyped and proxies in high LD with an index SNP (D 0 ¼ 1, r 2 Z0.8) were available for a further 8 SNPs. Of these 21 SNPs, the same direction of effect between our independent ImmunoChip study and the PGC-BD data were seen for 15 SNPs (71%), with a significant sign test for consistency of effect (sign test P-value ¼ 0.039). Supplementary Table 3 indicates the proxy SNP used and the LD between the proxy and the original PGC-BD SNP. A combined analysis had been performed by the PGC analyzing the primary and replication samples for all 34 SNPs and it is this P-value we used. In the combined data sets (PGC-BD and independent ImmunoChip), the two previously reported SNPs in CACNA1C and ODZ4 showed increased evidence of GWS association, rs125766774 in ODZ4 (Pvalue ¼ 6.20 Â 10 À 9 , OR ¼ 0.90) and rs4765913 located in CAC-NA1C (P-value ¼ 9.78 Â 10 À 10 , OR ¼ 1.14; Table 2 ). In addition, GWS evidence for association was established with rs7296288 on chromosome 12 (P ¼ 8.97 Â 10 À 9 , OR ¼ 0.902). The three regions of strongest association reported in the Ferreira et al. study 3 were ANK3, CACAN1C and chromosome 15q14. Comparison of the independent BD cases with the independent controls showed an association with rs1006737 (P ¼ 4.09 Â 10 À 4 ) and rs1024582 (P ¼ 6.28 Â 10 À 4 ) in CACNA1C, with the same risk alleles. We also noted support for the previously identified SNPs on chromosome 15q14 (rs12899449 & rs2172835, P-value, 0.066 and 0.044, respectively). We saw no replication for the two SNPs that previously showed strongest association in ANK3, rs10994336 and rs1938526 (Table 3 ).
In addition, we performed fine mapping of recombination regions around the most significantly associated SNPs in CACNA1C and ANK3. The additional cases and controls genotyped in our earlier GWAS 6 were included in these analyses (total of 2586 BD cases and 4322 controls). Both Hapmap and 1K genome (September 2009 release) SNPs were genotyped. For ANK3, 1075 SNPs in a recombination region of approximately 498 kb around rs10994336 were genotyped. The most associated SNP was rs10821708 with a P-value of 0.0017 (OR ¼ 1.21). For CACNA1C, fine mapping was performed around rs1006737 encompassing approximately 159 kb including 293 SNPs. The most significantly associated SNP was rs882194 (P-value, 5.53 Â 10 À 5 , OR ¼ 1.22; Supplementary Figure 2 ). There was no evidence of more than one independent signal after conditioning on rs882194.
DISCUSSION
We report replication of previous BD GWAS findings in an independent BD and control sample set from the United Kingdom. Combining our data with the largest BD meta-analysis to date, the PGC-BD, 5 we observed two novel GWS associations on chromosome 20 at TRPC4AP and on chromosome 12 between RHEBL1 and DHH. In addition, the two independent SNPs reported as showing GWS by the PGC-BD, 5 rs4765913 and rs12576775, lying in CACNA1C and ODZ4 respectively, also showed increased evidence of association by approximately a level of magnitude for both loci.
Our original aims were to replicate findings from the BD metaanalysis of Ferreira et al. 3 and to refine previously reported association signals at CACNA1C and ANK3. We found independent support for the associations at CACNA1C and chromosome 15q14, , which are not covered by the top 34 SNPs in the PGC-BD primary and replication combined study. 5 OR is predicted toward allele 1; P-value in bold indicates genome-wide statistical significance.
Genome-wide significant associations in bipolar disorder EK Green et al WDR82, TWF2,  TNNC1,TMEM110, TLR9,  STAB1,SPCS1, SNORD69,  SNORD19, SNORD19B,  SFMBT1, SEMA3G, RFT1,  PRKCD, PPM1M, PHF7,  PBRM1, NT5DC2, NISCH,  NEK4, MUSTN1,  LOC440957, ITIHI, ITIH3,  ITIH4, GNL3, GLYCTK,  GLT8D1, 
PTPRT
Abbreviations: A1/2, allele 1/2; BD, bipolar disorder; CHR, chromosome; LD, linkage disequilibrium; OR, odds ratio is predicted toward allele 1; PGC-BD, Psychiatric Genome-Wide Association Study Consortium Bipolar Disorder; P GC , genomic control P-value; Position, base pair position according to NCBI Build 36.1; rsxx**, indicates a proxy SNP from the ImmunoChip data have been used in the analysis; SNP, single-nucleotide polymorphism. P-values in bold are genome-wide significant (i.e. Po5 Â 10 À 8 ). Table 3 . Analysis of three chromosomal regions that previously showed association with BD at Po10 À 6 in meta-analysis study 3 Ferreira et al. Genome-wide significant associations in bipolar disorder EK Green et al but not at ANK3. In fine mapping of CACNA1C, an alternative SNP (rs882914) was more significantly associated than the original variant that had showed strongest association (rs1006737). The SNPs rs1006737 and rs882194 are both intronic SNPs with no known functional role, and are in moderate LD (D 0 ¼ 0.998 and r 2 ¼ 0.64). We did not observe a second independent association signal within the region studied.
Within ANK3 neither of the two previously associated metaanalysis SNPs 3 were associated in our independent sample. This is unlikely to be a type II error as our sample was large and provided power of 97% (a ¼ 0.05) to detects effects of the size observed by Ferreira et al. 3 The most strongly associated SNP in our independent sample analysis was rs1821708 with a P-value of 0.0017. This signal is of borderline statistical significance after correcting for multiple testing: it would be nominally significant at Po0.05 following Bonferroni multiple testing correction for the 124 independent SNPs (r 2 40.5) genotyped, but not significant after correcting for all 1075 SNPs examined. We note that, in similar vein to our current finding, in the PGC-BD meta-analysis study 5 the primary association reached GWS but there was no association at ANK3 in the replication sample. This observation was interpreted as being consistent with an overestimation of the original ORs, rather than disproving the association. To resolve this and make a conclusive decision regarding the involvement of ANK3 may involve the genotyping of a large number of additional samples.
Combining our ImmunoChip independent data with the PGC-BD meta-analysis data provided support for the GWS associations at CACNA1C and ODZ4, plus two novel GWS associations. The first novel region is located on chromosome 20 at rs3818253 for which combining the independent ImmunoChip data with the primary PGC-BD data gave a P-value of 3.88 Â 10 À 8 (OR ¼ 1.16). SNPs in this region were not genotyped in the replication sample in the PGC study, 5 but were included in this study because the P-value was o1 Â 10 À 3 in the Ferreira et al., meta-analysis (rs3818253 Pvalue, 5.3 Â 10 À 4 ). 3 Interestingly, rs3818253 was the most significantly associated SNP in our independent sample on the ImmunoChip. Three genes lie in the LD block implicated, GSS, MYH7B and TRPC4AP, encoding glutathione synthetase, myosin-7B, and transient receptor potential cation channel, subfamily C, member 4 associated protein, respectively. rs3818253 lies in the intron of TRPC4AP. Further detailed analysis of this chromosomal region in additional samples for replication and refinement of the association signal is needed.
Chromosome 12q13.1 at rs7296288 is the second chromosomal region showing GWS association. rs7296288 lies intergenic between RHEBL1 and DHH, 16.2 and 3.2 kb up and downstream of the SNP, respectively. The genes encode Ras homolog enriched in brain-like 1, and desert hedgehog protein. Association at this SNP did not quite reach the level of GWS in the PGC-BD combined analysis on its own (P-value, 5.4 Â 10
There has been substantial debate about the most appropriate way to correct for multiple testing in GWAS, including cogent arguments about the relative benefits of frequentist and Bayesian approaches to data evaluation (see, for example, Box 1 in WTCCC 6 ). Within the context of the frequentist approach to genome-wide experiments, the gold standard for statistical significance is GWS using all available data: in other words, correcting for all independent tests across the genome and putting together by meta-analysis all available, relevant data sets. Our reports of novel GWS signals at rs7296288 on chromosome 12 and rs3818253 on chromosome 20q11.2 meet this stringent test. When we consider a less stringent test of support for association within our sample, for example, looking at whether we find association support for the top three associations in the Ferreira et al.
3 meta-analysis, a simple Bonferroni correction for three independent tests is appropriate. With that correction, we find support for one of the three loci: CACNA1C.
The gender ratio for the new independent BD sample (71% female:29% male) is broadly in line with previous bipolar samples recruited and reported by us (for example, WTCCC 6 ). However, this female predominance is different from the ratio in our controls (53% female:47% male) and from the usually quoted equal gender prevalence of BD in the population. This raises the possibility of a gender-specific effect influencing our results. There are two observations that make this extremely unlike. The first is that strongly associated loci reported to date, and replicated within this study, have not been shown to have any genderspecific effect of association. Thus, a priori, we do not expect gender-specific effects. Second, an analysis within our current sample shows no evidence of differences in allele frequency distributions between male and female bipolar cases. Hence, we can be confident that differences in gender distribution in our case and control samples did not cause or influence the findings. The predominance of females in our sample also raises the possibility that our findings may not generalize to samples with more equal gender ratio. Although we have no reason to think this will be the case, it is a possibility and points to the potential benefits of taking account of a wide range of clinical variables (not just gender) when analyzing data across multiple clinical samples. 15 In summary, we have provided additional support for prior association findings in CACNA1C, ODZ4 and at chromosome 15q14. In addition, combined analysis with the PGC-BD data show two novel GWS associations. First, in a region of high LD at TRPC4AP on chromosome 20q11.2, which has not been highlighted previously and second at a region on chromosome 12q13.1 with a SNP located between RHEBL1 and DHH.
